Chen, Wensheng
Pilling, Darrell
Gomer, Richard H.
Funding for this research was provided by:
National Institutes of Health (HL118507)
Article History
Received: 24 July 2017
Accepted: 19 November 2017
First Online: 4 December 2017
Ethics approval and consent to participate
: All protocols were approved by the local ethical committees and performed in accordance with national guidelines and regulations. Human peripheral blood was collected from healthy adult volunteers who gave written consent and with specific approval from the Texas A&M University human subjects Institutional Review Board.
: Not applicable.
: We have read the journal’s policy, and the authors of this manuscript have the following competing interests: Rice University has patents on the use of SAP to inhibit fibrosis. D.P. and R.H.G. are co-founders of and have equity in Promedior, a company that is developing SAP as a therapeutic. D.P. and R.H.G. receive a share of royalties paid by Promedior to Rice University. Note that we observed no effects of SAP in this manuscript. The authors report no conflicts of interest with regard to the use of CRP or PTX3.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.